(2)
BioNTech to establish first regional hub in Asia Pacific region in Singapore
Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide a rapid response capability for south east Asia against potential future pandemic threats
Expansion plan supported by the Singapore Economic Development Board (EDB)
MAINZ, GERMANY, May 10, 2021 -
BioNTech SE(Nasdaq: BNTX, BioNTech or the Company ) today announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for south east Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing facility in Singapore with support from the Singapore Economic Development Board. The new facility will provide regional and global supply capacity of BioNTech s growing pipeline of mRNA-based product candidates, as well as a rapid response production
BioNTech plans to build manufacturing site, regional headquarters in Singapore
Photo: CDC/Unsplash
May 10, 2021
BioNTech said on Monday it plans to set up a regional headquarters and build a new manufacturing site for its vaccines based on messenger RNA technology (mRNA) in Singapore, in the latest move to expand its production network.
The biotech company said the Singapore production facility will have an estimated annual capacity of several hundred million doses of mRNA-based vaccines depending on the specific type, once it is operational in 2023.
BioNTech said its expansion plans were supported by the Singapore Economic Development Board and would increase the global supply of mRNA-based vaccines and establish a production facility in Southeast Asia to respond rapidly to future pandemics.
BioNTech SE
BioNTech to Establish Regional Headquarters for South East Asia and First mRNA Manufacturing Facility in Singapore
BioNTech to Establish Regional Headquarters for South East Asia and First mRNA Manufacturing Facility in Singapore
BioNTech to establish first regional hub in Asia Pacific region in Singapore
Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide a rapid response capability for south east Asia against potential future pandemic threats
Expansion plan supported by the Singapore Economic Development Board (EDB)
MAINZ, GERMANY, May 10, 2021
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for south east Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manu
BioNTech co-developed a vaccine for Covid-19 with U.S. drugmaker Pfizer using mRNA technology which makes use of genetic material to provoke an immune response against the virus.
BioNTech s expansion is supported by the Singapore Economic Development Board a government agency under the trade ministry. The venture is expected to create up to 80 additional jobs in the country. Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities, Ugur Sahin, CEO and co-founder of BioNTech, said in a statement. With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world.
FILE PHOTO: A healthcare worker prepares a dose of the Pfizer/BioNTech coronavirus disease (COVID-19) vaccine, which was authorized by Canada to be used for children aged 12 to 15, at Woodbine Racetrack pop-up vaccine clinic in Toronto, Ontario, Canada May 5, 2021. REUTERS/Carlos Osorio SINGAPORE: BioNTech SE today announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for southeast Asia in Singapore.
The German biotechnology company also plans to establish a fully integrated messenger RNA (mRNA) manufacturing facility in the republic with support from the Singapore Economic Development Board. Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities,” said its Chief Executive and Co-founder, Ugur Sahin, in its website.